Clinical Trials Browser

Recurrence × Epirubicin × Genitourinary × Clear all

NCT05146635 2022-01-11

Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial

Phase NA Unknown

Urinary Bladder Neoplasms, Recurrence, Disease Progression